Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

← catalyst calendar

NCT05442047

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
105actual
Sites
39
Countries
Canada, Czechia, France +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-08-02actualWhen the study began enrolling
Primary completion2025-02-17actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-05-13actualThe whole study's end, after follow-up
First posted2022-07-01actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-02-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions

  • Drug: NNC6019-0001
  • Drug: Placebo (NNC6019-0001)

Primary outcomes

what the primary-completion date above is the date OF
Change in 6-minute walk test (6-MWT)
measured From baseline (week 0) to visit 15 (week 52)
Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)
measured From baseline (week 0) to visit 15 (week 52)

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed